Phase 2 randomized placebo-controlled EASE study evaluating the safety, tolerability, pharmacodynamics, and exploratory efficacy of EP262 (150 mg oral once daily), an MRGPRX2 small-molecule antagonist, versus placebo over 6 weeks in adults aged 18–80 with moderate-to-severe atopic dermatitis (3–20% BSA affected, vIGA-AD ≥ 3).
EP262 was well tolerated (TEAEs in 19.0% EP262 vs 63.6% placebo; none treatment-related; no grade ≥ 3 or serious events), but showed no meaningful efficacy: EASI change from baseline −14.9% (EP262) vs −40.7% (placebo); vIGA-AD 0/1 with ≥2-point improvement 21.1% vs 27.3%; PP-NRS change −26.7% vs −25.1%; no differential gene expression or epidermal thickness changes.
- Very small sample size (n=32, 2:1 randomization) severely limits power to detect efficacy signals. - Short 6-week treatment duration may be insufficient to capture meaningful pharmacodynamic or clinical effects. - Full text was not retrievable; key methodological details (e.g., stratification, blinding procedures) could not be verified.
EP262, an oral MRGPRX2 antagonist, did not improve atopic dermatitis outcomes versus placebo at 6 weeks in this small phase 2 trial. Clinicians should not expect this agent to be a near-term treatment option based on current evidence.
